Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Laboratory management of Crimean-Congo haemorrhagic fever virus infections: perspectives from two European networks

  • Bartolini, Barbara
  • Gruber, Cesare EM
  • Koopmans, Marion
  • Avšič, Tatjana
  • Bino, Sylvia
  • Christova, Iva
  • Grunow, Roland
  • Hewson, Roger
  • Korukluoglu, Gulay
  • Lemos, Cinthia Menel
  • Mirazimi, Ali
  • Papa, Anna
  • Sánchez-Seco, María Paz
  • Sauer, Aisha V
  • Zeller, Hervè
  • Nisii, Carla
  • Capobianchi, Maria Rosaria
  • Ippolito, Giuseppe
  • Reusken, Chantal B
  • Di Caro, Antonino
BackgroundCrimean-Congo haemorrhagic fever virus (CCHFV) is considered an emerging infectious disease threat in the European Union. Since 2000, the incidence and geographic range of confirmed CCHF cases have markedly increased, following changes in the distribution of its main vector, Hyalomma ticks.AimsTo review scientific literature and collect experts' opinion to analyse relevant aspects of the laboratory management of human CCHF cases and any exposed contacts, as well as identify areas for advancement of international collaborative preparedness and laboratory response plans.MethodsWe conducted a literature review on CCHF molecular diagnostics through an online search. Further, we obtained expert opinions on the key laboratory aspects of CCHF diagnosis. Consulted experts were members of two European projects, EMERGE (Efficient response to highly dangerous and emerging pathogens at EU level) and EVD-LabNet (Emerging Viral Diseases-Expert Laboratory Network).ResultsConsensus was reached on relevant and controversial aspects of CCHF disease with implications for laboratory management of human CCHF cases, including biosafety, diagnostic algorithm and advice to improve lab capabilities. Knowledge on the diffusion of CCHF can be obtained by promoting syndromic approach to infectious diseases diagnosis and by including CCHFV infection in the diagnostic algorithm of severe fevers of unknown origin.ConclusionNo effective vaccine and/or therapeutics are available at present so outbreak response relies on rapid identification and appropriate infection control measures. Frontline hospitals and reference laboratories have a crucial role in the response to a CCHF outbreak, which should integrate laboratory, clinical and public health responses.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge

  • Moreno, Sandra
  • Calvo Pinilla, Eva María
  • Devignot, S.
  • Weber, Friedemann
  • Ortego, Javier
  • Brun Torres, Alejandro
25 Pág., Many ruminant diseases of viral aetiology can be effectively prevented using appropriate vaccination measures. For diseases such as Rift Valley fever (RVF) the long inter-epizootic periods make routine vaccination programs unfeasible. Coupling RVF prophylaxis with seasonal vaccination programmes by means of multivalent vaccine platforms would help to reduce the risk of new RVF outbreaks., AB is supported by grants AGL2014-57430R and AGL2017-83226R from the Spanish Ministry of Science, and grant S2018/BAA 4370 from Comunidad de Madrid R&D in Technologies Program. JO is supported by grants AGL2014-57430R and AGL2017-82570R from the Spanish Ministry of Science and Innovation and European Union’s Horizon 2020 research and innovation program under grant proposal 727393-2. SMF is a recipient of a pre-doctoral fellowship program from the Spanish Ministry of Science and innovation. FW is supported by the CCHF Vaccine consortium that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 732732, and by the Swedish Research Council(Vetenskapsrådet, VR) section Research Environment, Infection Biology (contract number 2018-05766). The funding sources had no involvement in the study design nor in the writing of the report and the decision to submit the article for publication, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Research and product development for Crimean-Congo haemorrhagic fever: priorities for 2024-30

  • Semper, Amanda E.
  • Fuente, José de la
Personal View: et al., Crimean–Congo haemorrhagic fever (CCHF) is a widely distributed and potentially fatal tick-borne viral disease with no licensed specific treatments or vaccines. In 2019, WHO published an advanced draft of a research and development roadmap for CCHF that prioritised the development and deployment of the medical countermeasures most needed by CCHF-affected countries. This Personal View presents updated CCHF research and development priorities and is the product of broad consultation with a working group of 20 leading experts in 2023–24. The strategic goals, milestones, and timelines have been revised and expanded to reflect scientific advances since 2019, including the identification of antibodies with therapeutic potential and the progression of four vaccine candidates through phase 1 clinical trials. This update emphasises the need for a One Health approach to manage CCHF, from integrated cross-sectoral surveillance to novel interventions that target ticks and their vertebrate hosts to reduce CCHF virus transmission to humans. The overarching vision for rapid diagnostics and specific therapeutics by 2028, followed by options to limit CCHF virus transmission and control disease by 2030, is deliberately ambitious and will only be achieved through coordinated international action from affected countries, funders, scientists, product developers, manufacturers, regulators, national authorities, and policy makers., JF declares a grant from the Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación, Spain (grant number MCIN/ AEI/10.13039/501100011033) and the EU–European Regional Development Fund (grant number BIOGAL PID2020–116761GB-I00). JF has also received support from the Federal University of Uberlândia and the Brazilian Federal Foundation for Support and Evaluation of Graduate Education (grant number 88887.936876/2024–00) to attend the 2024 Annual Scientific Meeting of the European Veterinary Parasitology College at the University of Agronomic Sciences and Veterinary Medicine, Bucharest, Romania. TF declares funding (paid to his institution) from GuardRX (not-for-profit) and the Pandemic Institute (Liverpool) for the UMIT-1 phase 1b Crimean–Congo haemorrhagic fever (CCHF) therapeutics trial in Türkiye; from the Medical Research Council (MRC) for the UMIT-2 phase 2b CCHF therapeutics trial in Türkiye and Iraq; from the MRC for the GeneDrive PCR platform and for development of a CCHF lateral flow test. SG has received grants (paid to his institution) from the German Research Foundation, European Commission, German Government, Coalition for Epidemic Preparedness Innovations (CEPI), and Kirmser Foundation; and has received speaker honoraria and support for attending meetings from WHO and CEPI. RH is in receipt of grant funding from the Biotechnology and Biological Sciences Research Council, the Defense Threat Reduction Agency, and the MRC to investigate CCHF virus genome reassortment, sequence CCHF virus variants, and develop diagnostics for low-resource settings; and is an investigator in the EU H2020-funded CCHFVaccine project. RH is a named inventor on a patent (PCT/GB2013/0503174; WO 2014/132013) for a vectored CCHF vaccine. GKob received federal funding from the Canadian Institute for Health Research to develop immunogens based on CCHF glycoproteins (2016–21), is an inventor on a patent for CCHF virus immunogenic compositions, and received funding from Université Laval and GUARDRx (not-for-profit) to attend meetings related to the original CCHF Research and Development (R&D) Roadmap (2018–20). AC, PCF, PJH, and JPG worked at the Wellcome Trust during the time that the CCHF Roadmap was being revised and this Personal View was written. TJGB, AES, and JW received support from WHO to attend meetings related to the original CCHF R&D Roadmap (2018–20). TJGB, AES, JW, and JO received funding from the Wellcome Trust (grant number 226729/Z/22/Z) to coordinate the 2023–24 update to the CCHF R&D Roadmap and to complete this Personal View. In addition, the Wellcome Trust covered convening costs for TJGB, AES, JW, VB, M-PP, LHB, TF, PBHF, SG, RH, BJ, JF, GP, AP, and HS to attend a meeting of the CCHF working group in London, UK (Feb 13–14, 2023). A, Peer reviewed